HTA
ABBV icon

Haber Trilix Advisors’s AbbVie ABBV Stock Holding History

Haber Trilix Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$24K Buy
+590
New +$25.8K ﹤0.01% 295

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Haber Trilix Advisors's ABBV Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in AbbVie (ABBV) in Q2 2013: 590 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #295 among its holdings.

1,287 funds tracked by Wall St. Rank hold ABBV as of Q2 2013.

  • Haber Trilix Advisors held 590 shares of AbbVie worth $24K as of Q2 2013.
  • AbbVie was a new Haber Trilix Advisors position in Q2 2013.
  • AbbVie made up ﹤0.01% of Haber Trilix Advisors's portfolio in Q2 2013, its #295 holding.
  • 1,287 funds tracked by Wall St. Rank held AbbVie as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.